← Back to scoreboard
HealthcareAMGN
Amgen
Most AI-advanced biologics company. 'Generative biology' approach — AI designs proteins rather than screening. AMPLIFY protein language model. deCODE genetics DGX SuperPOD for human diversity atlas.
AI Impact Score
7.2/10
↑ Positive
Scoring Breakdown
Sector Base
7
AI Revenue Exposure
7
Moat Durability
8
Disruption Risk (lower=better)
4
AI Adoption Maturity
9
Scenarios
Bull Case
deCODE + AMPLIFY is unique proprietary data + AI moat. Population-scale genomic data creates target identification capabilities no competitor can replicate.
Bear Case
Generative biology is scientifically compelling but clinical validation gap remains. Significant GLP-1 competition exposure with Maritide.
Key Factors to Watch
- ●AMPLIFY protein language model: 2x success rate and 2x timeline compression documented
- ●deCODE genetics DGX SuperPOD: non-replicable proprietary genomic data moat
- ●Generative biology designs proteins from scratch — fundamentally different pipeline economics
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-03-08 | 7.2 | Positive | Score 7.3→7.2 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 7.3 | Positive | Score 7.4->7.3 (are 8->7, aam 8->9). External research cross-ref: deCODE 200+ PB data moat and AMPLIFY model are leading but revenue is from drug sales (are=7). Freyja SuperPOD, dedicated CTO + SVP of AI justify aam=9 |
| 2026-03-08 | 7.4 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-04-25
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.